New Study Highlights CHMA1004's Potential in Reducing Anxiety
Professor Jaanus Harro and his research team have recently published an important study in Acta Neuropsychiatrica showcasing the effects of METTL3/METTL14 activators on anxiety-related behaviours.
In their work, they tested Chemestmed's methylation repairer, CHMA1004, demonstrating its potential in reducing anxiety in preclinical models. The study also explores the neurochemical changes and gene expression related to dopamine neurons and stress response, reinforcing the therapeutic potential of RNA m6A methylation activators for neuropsychiatric drug development.
This publication underscores the growing importance of RNA regulation in neuropsychiatric research, highlighting the potential of RNA m6A methylation activators as promising therapeutic agents for addressing anxiety and other related disorders.